ACE2 Protein, Paguma larvata (HEK293, hFc)

ACE2 is an important carboxypeptidase in the renin-angiotensin system, converting angiotensin I to anti-hypertrophic angiotensin 1-9 and vasoconstrictor angiotensin II to vasodilator angiotensin 1-7, thereby regulating cardiovascular homeostasis. It can remove the C-terminal residues of vasoactive peptides and cleave a variety of biological peptides. ACE2 Protein, Paguma larvata (HEK293, hFc) is the recombinant ACE2 protein, expressed by HEK293 , with C-hFc labeled tag.

ACE2, an essential counter-regulatory carboxypeptidase in the renin-angiotensin hormone system, emerges as a pivotal regulator of blood volume, systemic vascular resistance, and cardiovascular homeostasis. Its multifaceted enzymatic activities include the conversion of angiotensin I to angiotensin 1-9, an anti-hypertrophic peptide in cardiomyocytes, and angiotensin II to angiotensin 1-7, a vasodilator with anti-proliferative properties that counterbalance the vasoconstrictor effects of angiotensin II. ACE2's repertoire extends to removing the C-terminal residue from vasoactive peptides such as neurotensin, kinetensin, and des-Arg bradykinin, while not affecting bradykinin. Additionally, ACE2 cleaves diverse biological peptides like apelins, casomorphins, and dynorphin A. Beyond its enzymatic roles, ACE2 assumes importance in amino acid transport, acting as a binding partner for the amino acid transporter SLC6A19 in the intestine, where it regulates trafficking, surface expression, and catalytic activity. In the context of microbial infection, ACE2 serves as a receptor for the human coronavirus SARS.

Others

HEK293

C-hFc

Q56NL1 (Q18-T740)

/

Extracellular Domain

QSTTEELAKTFLETFNYEAQELSYQSSVASWNYNTNITDENAKNMNEAGAKWSAYYEEQSKLAQTYPLAEIQDAKIKRQLQALQQSGSSVLSADKSQRLNTILNAMSTIYSTGKACNPNNPQECLLLEPGLDNIMENSKDYNERLWAWEGWRAEVGKQLRPLYEEYVALKNEMARANNYEDYGDYWRGDYEEEWTGGYNYSRNQLIQDVEDTFEQIKPLYQHLHAYVRAKLMDTYPSRISRTGCLPAHLLGDMWGRFWTNLYPLTVPFGQKPNIDVTDAMVNQNWDARRIFKEAEKFFVSVGLPNMTQGFWENSMLTEPGDGRKVVCHPTAWDLGKGDFRIKMCTKVTMDDFLTAHHEMGHIQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPNHLKTIGLLSPAFSEDNETEINFLLKQALTIVGTLPFTYMLEKWRWMVFKGAIPKEQWMQKWWEMKRNIVGVVEPVPHDETYCDPASLFHVANDYSFIRYYTRTIYQFQFQEALCQIAKHEGPLHKCDISNSTEAGKKLLEMLSLGRSEPWTLALERVVGAKNMNVTPLLNYFEPLFTWLKEQNRNSFVGWDTDWRPYSDQSIKVRISLKSALGEKAYEWNDNEMYLFRSSIAYAMREYFSKVKNQTIPFVEDNVWVSDLKPRISFNFFVTFSNNVSDVIPRSEVEDAIRMSRSRINDAFRLDDNSLEFLGIEPTLSPPYRPPVT

≥ 95%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.